Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 02, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in their interests in the company's Ordinary Shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director share allocations and does not contain financial performance data.
Material Changes
The material change reported is the provisional allocation of share awards to Non-Executive Directors on December 31, 2006, resulting from the Annual Re-investment of Dividends paid throughout 2006. These allocations were communicated to the Company and the Directors on January 2, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure Rule 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Type: Annual Dividend Reinvestment awards allocated to Non-Executive Directors.
- Allocation Date: December 31, 2006 (notified January 2, 2007).
- Directors Involved: Sir Ian Prosser, Sir Christopher Gent, Mr Lawrence Culp, Sir Crispin Davis, Sir Deryck Maughan, Dr Ronaldo Schmitz, Mr Tom de Swaan, and Sir Robert Wilson.
- Share Classes: Awards were made in both Ordinary Shares (GBP) and American Depository Shares (ADSs).
- Financial Data: No financial performance metrics are included in this specific filing.